These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 38149637

  • 1. Development of a novel direct compressible co-processed excipient and its application for formulation of Mirtazapine orally disintegrating tablets.
    Loke YH, Chew YL, Janakiraman AK, Lee SK, Uddin ABMH, Goh CF, Kee PE, Ng HS, Ming LC, Liew KB.
    Drug Dev Ind Pharm; 2024 Jan; 50(1):36-44. PubMed ID: 38149637
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Characterization, optimisation and process robustness of a co-processed mannitol for the development of orally disintegrating tablets.
    Soh JL, Grachet M, Whitlock M, Lukas T.
    Pharm Dev Technol; 2013 Feb; 18(1):172-85. PubMed ID: 22582882
    [Abstract] [Full Text] [Related]

  • 4. Formulation studies for mirtazapine orally disintegrating tablets.
    Yıldız S, Aytekin E, Yavuz B, Bozdağ Pehlivan S, Ünlü N.
    Drug Dev Ind Pharm; 2016 Feb; 42(6):1008-17. PubMed ID: 26530146
    [Abstract] [Full Text] [Related]

  • 5. Application of Co-processed Excipient as a Novel Method to Compound Orally Disintegrating Tablets.
    Liew KB, Hii SH, Chew YL, Ming LC, Uddin AH, Sarker ZI.
    Int J Pharm Compd; 2022 Feb; 26(3):255-263. PubMed ID: 35657749
    [Abstract] [Full Text] [Related]

  • 6. Investigating the Impact of Co-processed Excipients on the Formulation of Bromhexine Hydrochloride Orally Disintegrating Tablets (ODTs).
    Woyna-Orlewicz K, Brniak W, Tatara W, Strzebońska M, Haznar-Garbacz D, Szafraniec-Szczęsny J, Antosik-Rogóż A, Wojteczko K, Strózik M, Kurek M, Jachowicz R, Mendyk A.
    Pharm Res; 2023 Dec; 40(12):2947-2962. PubMed ID: 37726407
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The influence of the API properties on the ODTs manufacturing from co-processed excipient systems.
    Krupa A, Jachowicz R, Pędzich Z, Wodnicka K.
    AAPS PharmSciTech; 2012 Dec; 13(4):1120-9. PubMed ID: 22941425
    [Abstract] [Full Text] [Related]

  • 11. Influence of Prosolv and Prosolv:Mannitol 200 direct compression fillers on the physicomechanical properties of atorvastatin oral dispersible tablets.
    Gowda V, Pabari RM, Kelly JG, Ramtoola Z.
    Pharm Dev Technol; 2015 Jun; 20(4):394-400. PubMed ID: 24397821
    [Abstract] [Full Text] [Related]

  • 12. Effect of processing methods on xylitol-starch base co-processed adjuvant for orally disintegrating tablet application.
    Bin LK, Helaluddin ABM, Islam Sarker MZ, Mandal UK, Gaurav A.
    Pak J Pharm Sci; 2020 Mar; 33(2):551-559. PubMed ID: 32276897
    [Abstract] [Full Text] [Related]

  • 13. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.
    Liu Y, Li P, Qian R, Sun T, Fang F, Wang Z, Ke X, Xu B.
    Drug Dev Ind Pharm; 2018 Aug; 44(8):1317-1327. PubMed ID: 29521132
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Computer-aided optimization of carbidopa/levodopa orally disintegrating tablets.
    Qin F, Wan C, Zhang Y.
    Drug Dev Ind Pharm; 2024 Apr; 50(4):331-340. PubMed ID: 38456721
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of Losartan Orally Disintegrating Tablets by Direct Compression: a Cost-Effective Approach to Improve Paediatric Patient's Compliance.
    Juan C, Gallo L, Gonzalez Vidal N.
    AAPS PharmSciTech; 2024 Apr 08; 25(4):79. PubMed ID: 38589718
    [Abstract] [Full Text] [Related]

  • 18. Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets.
    Gulsun T, Akdag Y, Izat N, Cetin M, Oner L, Sahin S.
    Pharm Dev Technol; 2020 Oct 08; 25(8):999-1009. PubMed ID: 32431206
    [Abstract] [Full Text] [Related]

  • 19. Microwave-Assisted Development of Orally Disintegrating Tablets by Direct Compression.
    Kande KV, Kotak DJ, Degani MS, Kirsanov D, Legin A, Devarajan PV.
    AAPS PharmSciTech; 2017 Aug 08; 18(6):2055-2066. PubMed ID: 27995465
    [Abstract] [Full Text] [Related]

  • 20. A Novel Lactose/MCC/L-HPC Triple-Based Co-Processed Excipients with Improved Tableting Performance Designed for Metoclopramide Orally Disintegrating Tablets.
    Dai X, Wang J, Yan B, Wang Q, Shen Y, Chen Y, Tian Y.
    Pharmaceutics; 2024 Jul 19; 16(7):. PubMed ID: 39065656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.